Summary of Vivesto's Business Update Conference Call Company Overview - **Company**: Vivesto - **Focus**: Oncology-driven biotech company specializing in innovative treatments for both human and veterinary medicine, particularly in cancer treatment [2][3] Key Programs Paccal Vet - **Description**: A proprietary formulation of paclitaxel designed for veterinary use, specifically targeting hemangiosarcoma in dogs and solid tumors in cats [7][22] - **Current Studies**: - **Dog Study**: Ongoing pilot study for dogs with splenic hemangiosarcoma, with 13 out of 18 dogs recruited. Expected top-line data in Q2 2026. Interim results show a median overall survival of 138 days compared to 60-86 days for standard care [24][25] - **Cat Study**: Dose-finding study for cats with various solid tumors, with 8 out of 12 cats recruited. Preliminary results indicate good tolerability and some clinical responses [26][28] Cantrixil - **Description**: A new proprietary chemotherapy agent targeting hematological cancers, currently in late-stage preclinical development [8][60] - **Focus**: Acute myeloid leukemia (AML), with plans to enter clinical development after 2026. Cantrixil has shown synergistic effects when combined with standard care agents [62][63] Market Dynamics - **Veterinary Oncology Growth**: The global companion animal health market is estimated to grow to $40 billion annually, driven by increased pet ownership and willingness to invest in advanced therapies [15][10] - **Unmet Medical Needs**: There is a significant demand for effective cancer treatments in veterinary medicine, with a high lifetime risk of cancer in pets, particularly in older dogs [16][17] Financial Strategy - **Capital Raise**: Vivesto is planning a rights issue fully supported by existing shareholders, expected to provide funding until mid-2027. Proceeds will support ongoing studies and regulatory activities [11][12] - **Partnership Opportunities**: The company aims to initiate partnering activities for both Paccal Vet and Cantrixil to enhance development speed and commercialization [12] Regulatory Support - **Designations**: Paccal Vet has received MUMS designation from the FDA, providing incentives for development in veterinary oncology. The EMA has also granted limited market classification [49][50] Conclusion - Vivesto is positioned at a critical juncture with a focused oncology strategy, strong backing from shareholders, and promising clinical data for its key programs. The company aims to address significant unmet medical needs in both human and veterinary oncology, with a clear path towards market approval and potential partnerships to enhance its capabilities [3][11][60]

Core Insights - Can-Fite BioPharma is advancing its veterinary oncology pipeline with Namodenoson, a Phase III cancer drug, targeting a market projected to reach $3.1 billion by 2030 [1] - The company is also developing Piclidenoson for osteoarthritis in pets, with clinical studies showing efficacy in dogs, representing a $3 billion market [1] Company Overview - Can-Fite BioPharma Ltd. is a biotechnology company focused on developing proprietary small molecule drugs for oncological and inflammatory diseases [4] - The company's lead drug candidate, Piclidenoson, has reported topline results in a Phase III trial for psoriasis and is in a pivotal Phase III trial [4] - Namodenoson is being evaluated in multiple clinical trials, including a Phase III trial for hepatocellular carcinoma and a Phase II study for pancreatic cancer [4] Upcoming Events - Can-Fite will participate in BioFIT 2025, a major European life sciences conference, to explore collaboration opportunities for Namodenoson [1][2] - The company aims to establish a second veterinary partnership focused on Namodenoson during the conference [2] Strategic Partnerships - Previous participation at BioFIT led to a successful partnership with Vetbiolix for Piclidenoson, potentially worth $325 million in royalty revenues for Can-Fite [2] - Can-Fite plans to hold partnering meetings with major animal health companies, including Elanco Animal Health and Zoetis, to discuss collaboration for Namodenoson [3]

Core Insights - Vivos Inc. reported a record-breaking first quarter for its IsoPet Animal Cancer Division, with a 150% year-over-year increase in treatment volume, highlighting its growing role in veterinary oncology [1][2] Group 1: Treatment Volume Surge - IsoPet treated 15 pets in Q1 2025, a 150% increase from Q1 2024, with a biweekly production schedule ensuring a steady supply of yttrium-90 (Y-90) hydrogel for targeted radiation [2] - Recent treatments included five pets in New Jersey and Texas, demonstrating the therapy's effectiveness in reducing tumors and improving quality of life [2] Group 2: Breakthrough Clinical Applications - IsoPet made significant advancements in equine oncology, treating four horses with ocular squamous cell carcinoma using direct cornea injections, a novel approach for this challenging condition [3] - Additional applications include palliative therapy for advanced equine jaw cancer and margin therapy post-tumor resection [3] Group 3: Clinic Expansion - Vivos Inc. activated three new certified clinics in Q1 2025, increasing the total to 14 clinics, with plans for further expansion to enhance access for pet owners [4] - The new clinics include specialized facilities for both small animals and equines, emphasizing the importance of trained veterinarians in the success of IsoPet [4] Group 4: Strategic Marketing and Community Engagement - IsoPet increased its presence at major veterinary conferences and utilized targeted newsletters and social media to drive treatment inquiries and community support [5] - Positive feedback from pet owners on social media highlights the effectiveness of IsoPet's non-surgical approach [5] Group 5: Market Positioning - The global veterinary oncology market, valued at $1.18 billion in 2023, is projected to grow at an 11.3% CAGR through 2030, driven by rising cancer diagnoses in pets [6] - IsoPet's minimally invasive therapy is well-positioned to meet this growing demand, offering a cost-competitive alternative to traditional radiation [6] Group 6: Leadership Perspective - The President & CEO of Vivos Inc. emphasized the transformative impact of IsoPet on veterinary oncology and the commitment to expanding access and exploring new applications [7][8]